查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1138265

2022-2029 年宏基因組測序全球市場

Global Metagenomic Sequencing Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

全球宏基因組測序市場的增長受到某些因素的推動，例如先進的技術平台、改進的基因組工具，以及政府和私人組織對大型測序項目的承諾和資金增加。它是主要的基因組測序市場之一。市場增長的因素。

在預測期內，先進的技術平台和改進的基因組工具有望推動全球宏基因組測序市場。

推動宏基因組測序市場增長的主要因素之一是更快的測序技術的持續發展以及處理產生的海量數據的各種方法的進步，這導致了研究人員無窮無盡的能力分析來自各種環境的微生物群落正在擴大。

越來越多地採用具有成本效益的技術開發，例如先進的生物信息學工具、高通量篩選 (HTS) 方法、藥物回收和下一代測序 (NGS)，正在推動市場增長。下一代 DNA 測序 (NGS) 技術的發展推動了分子生物學研究，帶來了多項發現和新見解。下一代 DNA 測序技術超越了歷史悠久的 DNA 測序，其應用超出了分子生物學的原理。

2019年5月28日，精準醫療生物技術公司Macrogen被韓國食品藥品安全部（MFDS）指定為臨床試驗標本分析實驗室。該認證將改善臨床診斷宏基因組學並使 Macrogen 受益。

因此，預計 DNA 測序技術的不斷進步將在預測期內推動市場增長。

政府和私人組織加大對大型測序項目的投入和資金投入

人們對遺傳病的認識不斷提高，政府加大對大型測序項目的承諾和資金投入是推動全球宏基因組測序市場增長的主要因素。例如，2019 年，QIAGEN 與多家英國組織建立了合作夥伴關係，以支持並在英國曼徹斯特建立一個全球基因組學園區。新的基因組健康創新園區將致力於生命科學、轉化科學和分子診斷領域的創新。

2019年11月，“人類百萬微生物組計劃”（MMHP）在第十四屆國際基因組學會議（ICG-14）上正式啟動。來自中國、法國、瑞典、丹麥、拉脫維亞等國的科學家將合作開展微生物宏基因組研究，未來3-5年，對腸道、皮膚、口腔、生殖道等100萬份微生物樣本進行測序分析。我們的目標是繪製人體微生物組圖，建立全球最大的人體微生物組數據庫。

阻礙宏基因組測序市場增長的因素

但是，也存在一些挑戰，例如對診斷測試的標準化和準確性的擔憂日益增加、對各種分離和鑑定技術的並行發展的需求、更高效和強大的生物資訊學工具以及熟練專業人員的短缺。阻礙市場增長。

細分分析

在預測期間（2022-2029 年），鳥槍法宏基因組測序技術領域預計將以最快的複合年增長率增長。

宏基因組測序市場按技術分為 16S rRNA 測序、鳥槍法宏基因組測序、全基因組測序和從頭組裝以及宏轉錄組學。在這些細分市場中，研究人員和醫療保健專業人員越來越多地採用鳥槍法宏基因組測序，鳥槍法測序提供了優於其他技術的一些優勢，並且基於宏基因組測序的鳥槍法宏基因組測序技術在預測期內以最快的速度增長，部分原因是以增加研究活動。鳥槍法測序可以檢測微生物群落的低豐度成員。與全基因組測序相比，鳥槍法宏基因組測序可以針對環境樣本中發現的所有生物的所有基因，並且可以針對僅一種生物的所有基因。

全球宏基因組測序市場報告提供對大約 40 多個市場數據表、45 多個圖表和 180 頁的訪問。

內容

第 1 章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 按產品/服務劃分的市場細分
  • 按技術劃分的市場細分
  • 按工作流程劃分的市場細分
  • 按應用劃分的市場細分
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因素
  • 促進因素
    • 加大對大型測序項目的投入和資金投入
    • 宏基因組學在各個領域的大應用
  • 抑制因素
    • 新興國家的預算限制
    • 缺乏熟練的專業人員
  • 商機
    • 用於數據管理的雲計算的興起
  • 影響分析

第 5 章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 臨床試驗
  • 定價分析
  • 監管分析
  • 保險報銷分析
  • 未滿足的需求

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按產品/服務分類

  • 儀器
  • 試劑和耗材
  • 分析和數據分析解決方案
  • 服務
  • 其他

第 8 章按工作流程

  • 數據處理和分析
  • 樣品製備和庫創建
  • 測序

第 9 章技術

  • Shotgun 宏基因組測序
  • 16S rRNA測序
  • 全基因組測序和從頭組裝
  • 元轉錄組學

第 10 章按應用程序

  • 藥物發現
  • 臨床診斷
  • 動物用藥
  • 在生態環境領域的應用
  • 工業領域的應用
  • 土壤微生物組應用
  • 其他

第 11 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 12 章競爭格局

  • 競爭場景
  • 市場情況/份額分析
  • 併購分析

第 13 章公司簡介

  • Thermo Fisher Scientific Inc.
    • 公司簡介
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Qiagen N.V.
  • BGI Group
  • DNAstar, Inc.
  • Eurofins Scientific
  • Illumina, Inc.
  • Macrogen, Inc.
  • Oxford Nanopore Technologies Ltd.
  • NuGEN Technologies, Inc.（A Wholly Owned Subsidiary of Tecan Trading AG）
  • F. Hoffmann-La Roche Ltd.
  • Perkinelmer, Inc.
  • Integragen SA
  • Microsynth AG
  • Novogene Co., Ltd.
  • Zymo Research Corporation（List Not Exhaustive）

第 14 章數據M

簡介目錄
Product Code: DMBT2643

Market Overview

Metagenomic Sequencing Market is expected to grow at a CAGR of 19.3% during the forecasting period (2022 - 2029). Metagenomics is a research field where genomic analysis of microbial DNA from environmental communities is studied. Metagenomic sequencing techniques enable scientists to analyze genes in a given sample. The method allows researchers to assess bacterial diversity and identify the presence of microbes in various environments. Steps involved in metagenomics sequencing include DNA extraction, library preparation, sequencing, assembly, annotation, and statistical analysis.

The Metagenomic Sequencing market study analysis offers an in-depth outlook on the market containing both quantitative, and qualitative data. It gives an outlook and forecast of the global market based on the Metagenomic Sequencing segmentation by product & service, workflow, and application. It also provides metagenomic sequencing market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global metagenomic sequencing market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Market Dynamics

The global metagenomic sequencing market growth driven by certain factors such as advanced technological platforms and improved genomic tools, increasing initiatives and funds by government and private organizations to large scale projects of sequencing are among the key factors driving the market growth.

Advanced technological platforms and improved genomic tools, is expected to drive the global metagenomic sequencing market during the forecast period;

One of the major factors driving the growth of the metagenomic sequencing market is the continuous development of faster sequencing techniques and advancements in different methods to cope with the huge data generated, which are expanding researchers' capacity to analyze microbial communities from an unlimited variety of environments.

The growing adoption of advanced bioinformatics tools, high throughput screening (HTS) methods, recovery of novel drugs, and development of cost-effective technologies such as next-generation sequencing (NGS) are driving the market growth. The development of Next Generation DNA Sequencing (NGS) technology has driven molecular biology research, leading to several discoveries and new insights. Next-generation DNA sequencing technology goes beyond long-established DNA sequencing with its applications that reach across the principles of molecular biology.

On May 28, 2019, a precision medicine biotechnology company, Macrogen, Inc. received South Korean accreditation of Good Clinical Lab Practices from the country's Ministry of Food and Drug Safety (MFDS) and designated as a clinical trial specimen analysis institution. It would benefit Macrogen with improvised clinical diagnostic metagenomics.

Hence, increasing technological advancements regarding DNA sequencing is expected to drive market growth over the forecast period.

Increasing initiatives and funds by government and private organizations to large scale projects of sequencing

The growing awareness of genetic disorders and increasing government initiatives and funds for large-scale projects of sequencing are among the major factor driving the growth of the global metagenomic sequencing market. For instance, in 2019, QIAGEN got into a partnership with multiple organizations in the UK to support and establish its global genomics campus in Manchester (UK). The new Genomic Health Innovation Campus will aim at innovation in life sciences, translational sciences, and the molecular diagnostics field.

Also, in November 2019, The "Million Microbiome of Humans Project" (MMHP) was officially launched at the 14th International Conference on Genomics (ICG-14). Scientists from China, France, Sweden, Denmark, Latvia, and other countries will cooperate in microbial metagenomic research, aiming to sequence and analyze one million microbial samples from intestines, skin, mouth, reproductive tract, and other organs in the next 3-5 years to draw a microbiome map of the human body and build the world's largest database of the human microbiome.

Factors hampering the growth of the metagenomic sequencing market

However, the market growth is hampered by several factors such as growing concerns towards the standardization and accuracy of diagnostic testing, its requirement for parallel advancement in various isolation and identification techniques, more efficient & robust bioinformatics tools, and lack of skilled professionals.

Segmentation Analysis

The shotgun metagenomic sequencing technology segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

By technology, the metagenomic sequencing market is segmented into 16S rRNA sequencing, shotgun metagenomic sequencing, whole-genome sequencing & de-novo assembly, and metatranscriptomics. Out of all these segments, the shotgun metagenomic sequencing technology is growing at the fastest growth rate over the forecast period, due to the growing adoption of shotgun metagenomic sequencing among researchers and healthcare professionals, several advantages offered by shotgun sequencing compared with other techniques, and the increasing number of metagenomic sequencing-based research activities. Shotgun sequencing can detect low abundance members of microbial communities. Shotgun metagenome sequencing can target all genes from all organisms found in an environmental sample, in contrast to the whole sequencing and targeting all genes from only one organism.

Geographical Analysis

North America region holds the largest market share of the global Metagenomic Sequencing market

North America region is dominating the global metagenomic sequencing market accounted for the largest market share in 2019, owing to technological advancements in the next-generation sequencing procedures along with its increasing applications, favorable initiatives by government and private bodies for the development and adoption of NGS-based metagenomics technologies, the wide adoption of metagenomic diagnostics in the region, and rising awareness of metagenomics sequencing services. The market players are collaborating to introduce new procedures with innovative technology. For instance, In 2019, Illumina and Thermo Fisher Scientific (U.S.) entered into a commercial agreement for the sales of Thermo Fisher's Ion AmpliSeq technology to researchers who use Illumina's NGS platforms.

Competitive Landscape

The metagenomic sequencing market is highly competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Illumina, Inc., Thermo Fisher Scientific Inc., Qiagen N.V., BGI Group, DNAstar, Inc., Eurofins Scientific, Macrogen, Inc., Oxford Nanopore Technologies Ltd., Brooks Automation, Inc. (GENEWIZ), Perkinelmer, Inc., among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the metagenomic sequencing market globally. For instance,

In 2019, Illumina acquired Pacific Biosciences, one of the leading providers of sequencing systems. This helped Illumina strengthen its sequencing product portfolio.

In 2019, Illumina acquired Edico Genome, a software provider for NGS.

In 2019, Microba had partnered with Macrogen to develop microbiome research services for international markets.

In 2019, Eurofins Scientific acquired TestAmerica, a leading environmental testing laboratory group in the US. This helped Eurofins strengthen its presence in the US market.

In November 2018, Brooks Automation, Inc. acquired the GENEWIZ group which will improve the company's global services of metagenomics sequencing.

In 2017, QIAGEN acquired Microsoft Corporation (US), management, visualization, and analysis software provider for bioinformatics, NGS, and cancer genomics.

COVID-19 Impact Analysis

The metagenomic sequencing market is positively impacted by COVID-19 as, throughout the COVID-19 pandemic, testing is a critical component of the response and rapidly increasing, which enables rapid identification and isolation of infected individuals. The Majority of this testing is PCR-based, detecting the presence of the SARS-CoV-2 virus only.

Next-generation sequencing (NGS) of the COVID-19 virus is providing powerful metagenomic data, that is combined with clinical data to search for effective treatments. Continous genomic and epigenomic analysis of SARS-CoV-2 is critical, used to determine the number of virus strains, how the virus is spread into new regions, number of introductions of the virus if there is community spread of the virus if outbreaks are linked, and how the virus is evolving.

Oxford Nanopore Technologies is doing the Metagenomic analysis of SARS-CoV-2 respiratory samples via Sequence-Independent Single Primer Amplification (SISPA) and nanopore sequencing.

Industry Analysis

The global metagenomic sequencing market provides in-depth analysis of the market based on various industry factors such as porter's five force analysis, supply chain analysis, regulatory analysis, clinical trials, pricing analysis etc, unmet needs, reimbursement analysis.

Key Companies to Watch

Illumina, Inc

Overview: Illumina, Inc. was incorporated in April 1998, and headquarter located in San Diego, California. The company develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serve the sequencing, genotyping and gene expression, and proteomics markets.

Product Portfolio: The company's product portfolio includes a wide range of highly interconnected products, including sequencing, genotyping, gene expression, and molecular diagnostic products. Illumina also offers metagenomic sequencing services, which further strengthens its market position.

Key Development: In 2019, Illumina and Lundbeck Foundation GeoGenetics Centre (Denmark) collaborated to generate one of the largest ancient genome datasets. This partnership will also help explore the relationship between the evolutionary history of select mental & neurological disorders and infectious pathogens.

The global metagenomic sequencing market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Product & Service
  • 3.2. Market snippet by Technology
  • 3.3. Market snippet by Workflow
  • 3.4. Market Snippet by Application
  • 3.5. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
  • 4.2. Drivers
    • 4.2.1. Increasing initiatives and funding for large-scale sequencing projects
    • 4.2.2. Large applications of metagenomics in various fields
    • 4.2.3. XX
  • 4.3. Restraints
    • 4.3.1. Budget constraints in developing countries
    • 4.3.2. Lack of skilled professionals
    • 4.3.3. XX
  • 4.4. Opportunity
    • 4.4.1. Emerging cloud computing for data management
  • 4.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Clinical Trials
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product & Service

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Service Segment
  • 7.3. Market Attractiveness Index, By Product & Service Segment
    • 7.3.1. Instruments*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Reagents & Consumables
    • 7.3.3. Analyses & Data Interpretation Solutions
    • 7.3.4. Services
    • 7.3.5. Others

8. By Workflow

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Workflow
    • 8.1.2. Market Attractiveness Index, By Workflow Segment
  • 8.2. Data Processing & Analysis *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 8.3. Sample Processing & Library Preparation
  • 8.4. Sequencing

9. By Technology

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology Segment
    • 9.1.2. Market Attractiveness Index, By Technology Segment
  • 9.2. Shotgun Metagenomic Sequencing*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 9.3. 16S rRNA Sequencing
  • 9.4. Whole Genome Sequencing & De Novo Assembly
  • 9.5. Metatranscriptomics

10. By Application

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
  • 10.3. Market Attractiveness Index, By Application Segment
    • 10.3.1. Drug Discovery*
      • 10.3.1.1. Introduction
      • 10.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 10.3.2. Clinical Diagnostics
    • 10.3.3. Veterinary Applications
    • 10.3.4. Ecological and Environmental Applications
    • 10.3.5. Industrial applications
    • 10.3.6. Soil Microbiome Applications
    • 10.3.7. Others

11. By Region

  • 11.1. Introduction
  • 11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 11.3. Market Attractiveness Index, By Region
  • 11.4. North America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Service
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Workflow
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. The U.S.
      • 11.4.7.2. Canada
      • 11.4.7.3. Mexico
  • 11.5. Europe
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Service
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Workflow
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. Germany
      • 11.5.7.2. The U.K.
      • 11.5.7.3. France
      • 11.5.7.4. Italy
      • 11.5.7.5. Spain
      • 11.5.7.6. Rest of Europe
  • 11.6. South America
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Service
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Workflow
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.6.7.1. Brazil
      • 11.6.7.2. Argentina
      • 11.6.7.3. Rest of South America
  • 11.7. Asia Pacific
    • 11.7.1. Introduction
    • 11.7.2. Key Region-Specific Dynamics
    • 11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Service
    • 11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Workflow
    • 11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.7.7.1. China
      • 11.7.7.2. India
      • 11.7.7.3. Japan
      • 11.7.7.4. Australia
      • 11.7.7.5. Rest of Asia Pacific
  • 11.8. The Middle East and Africa
    • 11.8.1. Introduction
    • 11.8.2. Key Region-Specific Dynamics
    • 11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Service
    • 11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Workflow
    • 11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 11.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Thermo Fisher Scientific Inc.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Qiagen N.V.
  • 13.3. BGI Group
  • 13.4. DNAstar, Inc.
  • 13.5. Eurofins Scientific
  • 13.6. Illumina, Inc.
  • 13.7. Macrogen, Inc.
  • 13.8. Oxford Nanopore Technologies Ltd.
  • 13.9. NuGEN Technologies, Inc. (A Wholly Owned Subsidiary of Tecan Trading AG)
  • 13.10. F. Hoffmann-La Roche Ltd.
  • 13.11. Perkinelmer, Inc.
  • 13.12. Integragen SA
  • 13.13. Microsynth AG
  • 13.14. Novogene Co., Ltd.
  • 13.15. Zymo Research Corporation (List Not Exhaustive)

14. DataM Intelligence

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us